



GlaxoSmithKline

GlaxoSmithKline
Pharmaceuticals Limited
Regd. Office: GSK House,
Dr. Annie Besant Road,
Worli, Mumbai - 400030.

Tel: +91 22 2495 9595
Fax: +91 22 2495 9494

6th April 2015

**NATIONAL STOCK EXCHANGE,
EXCHANGE PLAZA, 5TH FLOOR,
PLOT No. C/1, G BLOCK,
BANDRA-KURLA COMPLEX,
BANDRA (EAST), MUMBAI
400051**

Dear Sir,

**SECURITIES & EXCHANGE BOARD OF INDIA
(Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

Pursuant to the Regulation 30(1) & 30(2) of the Securities & Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and as advised by your Stock Exchange we enclose herewith confirmations for the holding of our promoters i.e. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited, Burroughs Wellcome International Limited and Castleton Investment Limited in respect of their shareholding in our Company as on 31st March 2015.

We hope the same is in order.

Thanking you,

 Yours faithfully
GlaxoSmithKline Pharmaceuticals Limited




Ajay Nadkarni
General Manager – Administration
& Company Secretary

Encl:

Corporate Identity Number
L24239MH1924PLC001151

Email id: askus@gsk.com
Web site address: www.gsk-india.com




भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) : Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Glaxo Group Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		30485250	35.99	35.99
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		30485250	35.99	35.99



भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

Signature of the Authorised Signatory

Place: BOSTON, UK

Paul Williamson
Authorised Signatory
For and on behalf of
Edinburgh Pharmaceutical Industries Limited
Corporate Director


Date: 31 March 2015.

Note:

¹ In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding


1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) : Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	GlaxoSmithKline Pte Ltd		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		20609774	24.33	24.33
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		20609774	24.33	24.33



Signature of the Authorised Signatory

Place: *Singapore*

Date: *2 April 2015*

A handwritten signature in black ink, consisting of a large, stylized 'S' or '8' shape with a horizontal line extending to the right.

Note:

¹ In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) : Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Eskaylab Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		5880000	6.94	6.94
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		5880000	6.94	6.94



भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

Signature of the Authorised Signatory

Paul Williamson
Authorised Signatory
For and on behalf of
Edinburgh Pharmaceutical Industries Limited
Corporate Director

Place: Brentford, UK


Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) : Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Burroughs Wellcome International Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		3360000	3.97	3.97
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		3360000	3.97	3.97



भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

Signature of the Authorised Signatory

Place: Brentford, UK

Date: 31 MARCH 2015

Paul Williamson
Authorised Signatory
For and on behalf of
Edinburgh Pharmaceutical Industries Limited
Corporate Director

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.



भारतीय प्रतिभूति और विनिमय बोर्ड Securities and Exchange Board of India

ANNEXURE-1

Format for Disclosure under Regulation 30(1) and 30(2) of SEBI
Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part-A: Details of Shareholding

1	Name of the Target Company (TC)	GlaxoSmithKline Pharmaceuticals Limited		
2	Name(s) of the stock exchange(s) where the shares of the TC are listed	Bombay Stock Exchange , BSE National Stock Exchange, NSE		
3	Particulars of the shareholder(s) : Name of person(s) together with Persons Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	Castleton Investment Limited		
4	Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w.r.t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As of March 31st of the year, holding of:				
a) Shares		3192238	3.77	3.77
b) Voting Rights (otherwise than by shares)		-	-	-
c) Warrants,		-	-	-
d) Convertible Securities		-	-	-
d) Any other instrument that would entitle the holder to receive shares in the TC.		-	-	-
Total		3192238	3.77	3.77



भारतीय प्रतिभूति और विनिमय बोर्ड
Securities and Exchange Board of India

Signature of the Authorised Signatory

Place: Ebene, Mauritius

Date: 31 March 2015

Note:

1 In case of promoter(s) making disclosure under regulation 30(2), no additional disclosure under regulation 30(1) is required.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(**) Part-B shall be disclosed to the Stock Exchanges but shall not be disseminated.